SCHEMBL21947322

SCHEMBL21947322

CCC(=O)c1cnn2cc(OCCN3CCCC3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 1/20 0.46
PSMB1 P20618 6/20 0.46
PSMB5 P28074 5/20 0.46
PSMB2 P49721 4/20 0.46
LTA4H P09960 2/20 0.44
ALDH1A1 P00352 4/20 0.44
THRB P10828 4/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
ADRA2C P18825 1/20 0.44
DRD4 P21917 1/20 0.44
ACHE P22303 1/20 0.44
SLC6A2 P23975 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902561 0.98 SMN1; SMN2 (0.46) KDM4ESMN1; SMN2GAAPSMB1PSMB5
SCHEMBL19902320 0.92 GAA (0.46) KDM4ESMN1; SMN2GAALTA4HALDH1A1
SCHEMBL19997286 0.90 SMN1; SMN2 (0.60) KDM4ESMN1; SMN2GAAPSMB1PSMB5
SCHEMBL17324759 0.90 MAOB (0.51) KDM4EPSMB1PSMB5PSMB2LTA4H
SCHEMBL15897907 0.87 LTA4H (0.49) KDM4ESMN1; SMN2PSMB1PSMB5PSMB2
SCHEMBL17454384 0.87 TSHR (0.48) KDM4EPSMB1PSMB5PSMB2LTA4H
SCHEMBL15882946 0.87 KDM4E (0.50) KDM4EPSMB1PSMB5PSMB2LTA4H
SCHEMBL17321453 0.86 KDM4E (0.48) KDM4EPSMB1PSMB5PSMB2LTA4H
SCHEMBL19902594 0.86 KDM4E (0.40) KDM4ESMN1; SMN2GAALTA4HALDH1A1
SCHEMBL19675530 0.85 KDM4E (0.50) KDM4EPSMB1PSMB5PSMB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829501-B2 Spiroheptane salicylamides and related compounds as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2020-11-10 US disclosed
US-20200131200-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829501-B2 Spiroheptane salicylamides and related compounds as inhibitors of ROCK ROCK1, MYLK, RHOA KDM4E 2121/4885SMN1; SMN2 823/4885GAA 4081/4885
US-20200131200-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK ROCK1, MYLK, RHOA KDM4E 2121/4885SMN1; SMN2 823/4885GAA 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.